Center for Advanced Studies (CAS) Research Focus CRISPR/Cas

https://cast.itunes.uni-muenchen.de/playlists/rg3dxll5P1/high_quality.rss

0 Followers 6 Episodes Claim Ownership

Emmanuelle Charpentier and Jennifer Doudna received the Nobel Prize for Chemistry in 2020 for their discovery in 2011 that CRISPR/Cas can be used to cut DNA at specific sites – a discovery that revolutionized research, especially in the fields of medicine and plant breeding. With this method, it is possible to make specific cuts and modifications to DNA with minimal cost and unparalleled efficiency (Genome Editing). Due to its simple handling, CRISPR/Cas-assisted gene editing is a technology t...

Episode List

Plant Engineering. Legal and Economic Aspects

Jul 25th, 2022 1:02 PM

Panel discussion with Dr. Oana Dima, Prof. Dr. Caroline Gutjahr, and Prof. Dr. Kai P. Purnhagen | Moderation: Christoph von Eichhorn. The dicussion is the final event in the lecture series "Out of the Box: CRISPR/Cas". The lecture series reflects on the consequences of the revolutionary gene editing technology CRISPR/Cas in the fields of natural sciences and medicine, as well as its societal significance.

Engineering our Ecosystems. Gene Drive and Local Drive

Jul 19th, 2022 2:05 PM

The evetn is part of the lecture series "Out of the Box: CRISPR/Cas". The lecture series reflects on the consequences of the revolutionary gene editing technology CRISPR/Cas in the fields of natural sciences and medicine, as well as its societal significance.

Human Engineering. Medical and Ethical Aspects and Prospects

May 23rd, 2022 1:06 PM

The lecture series reflects on the consequences of the revolutionary gene editing technology CRISPR/Cas in the fields of natural sciences and medicine, as well as its societal significance. The top-class speakers of the series include Kay Davies (Oxford), Kevin M. Esvelt (MIT), Caroline Gutjahr (TUM), Henry T. Greely (Stanford), Dirk Inzé (Gent), Greg Newby (Broad Institute), Kai P. Purnhagen (Bayreuth), Pamela C. Ronald (UC Davis) and Jörg Vogel (HIRI/Würzburg). The lecture series is part of the CAS Research Focus "CRISPR/Cas" . The spokesperson of this Research Focus is Prof. Dr. Eckhard Wolf (LMU).

Genome Editing to Create Personalized Safe and Effective Medicines

Apr 1st, 2022 2:06 PM

Genome editing gives precise control of the type of genetic modification made to a cell. Hematopoietic stem cells have pharmacologic properties of durability and output that still remain untapped. Matthew Porteus and his group are using genome editing of hematopoietic stem cells to develop new classes of drugs to treat patients.

Safety and Efficacy of CRISPR/Cas9 based Gene edited Hematopoietic Stem and Progenitor Cells in Hemoglobinopathies

Apr 20th, 2021 1:08 PM

Sickle cell disease is one of the most prevalent diseases worldwide. Even optimal conventional care has demonstrated inferiority compared to curative options such as hematopoietic stem cell transplantation. Gene editing promises an elegant alternative cure to all patients lacking a matched donor, potentially avoiding many of the transplantrelated complications. | Selim Corbacioglu is Professor for Pediatric and Adolescent Medicine as well as Director of the department for Pediatric Hematology, Oncology and Hematopoietic Stem-Cell Transplantation at the University Hospital Regensburg. 2019, he was able to succesfully treat a beta-thalassemia-patient by means of the CRISPR/Cas9 gene therapy for the first time.

More Episodes